Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

MADISON, Wis., May 11, 2022 – Exact Sciences Corp., a global leader in advanced cancer diagnostics, today announced the American Urological Association (AUA) updated their guidelines to include genomic assays, such as the Oncotype DX Genomic Prostate Score® (GPS™) test, when treating men with localized prostate cancer. The 2022 guidelines now state that clinicians may selectively use tissue-based genomic biomarkers when added risk-stratification may alter clinical decision-making. Exact Sciences will exclusively offer the at-a-glance booklets of the prostate cancer guidelines and exhibit its full portfolio of prostate cancer genomic tests at booth #647 during the AUA 2022 Annual Meeting from May 12-16 in New Orleans. This is the first in-person AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urologic genomic assays, including the Oncotype DX® GPS test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer.

"We're pleased that the updated guidelines recognize the impact genomic assays can have on treatment decision making for men with localized prostate cancer," said Daniel Shoskes, MD, MSc, FRCS(C), Medical Director of Urologic Oncology Medical Affairs at Exact Sciences and Emeritus Professor of Urology at The Cleveland Clinic. "While every patient is unique, clinical guidelines can help physicians offer the best evidence-based care using the most current data. The Oncotype DX GPS test is one of the most rigorously studied assays in localized prostate cancer patients, helping physicians refine risk stratification and make decisions between active surveillance and definitive treatment in low-risk patients, and to determine treatment intensity in higher-risk patients."

Key AUA activities featuring the Oncotype portfolio during the meeting include: